Catalent agrees two joint ventures in China
Will expand its softgel technologies and clinical supply solutions businesses in the region
Catalent Pharma Solutions has set up two joint ventures in China for its softgel technologies and clinical supply solutions businesses to broaden its offerings in the Chinese market.
The US firm has pledged to make additional investments in these two facilities over the next several years.
No financial details have been released.
In the first joint venture, Catalent has agreed to acquire a majority share in Haining-based, privately held Zhejiang Jiang Yuan Tang Biotechnology, a manufacturer of nutritional softgel products for Chinese and Asia Pacific markets. The company employs 120 people. Catalent says it will work with regulators for future expansion into OTC and prescription softgel manufacturing in China.
In the second agreement, Catalent and ShangPharma Corporation, a China-based pharmaceutical and biotechnology research and development outsourcing company, have formed a joint venture called Catalent (Shanghai) Clinical Trial Supplies Co. A new 31,000ft2 facility in Shanghai, which is currently under construction, will be the first in China to provide end-to-end solutions for clinical trial supplies, including comparator sourcing, primary and secondary packaging and labelling, and storage and distribution.
Catalent’s President and CEO, John Chiminski said: ‘As part of our growth strategy, these initial steps enable us better to serve the important Chinese market for both global and domestic customers. Our clients and their patients will benefit from access to Catalent’s advanced technologies and solutions, together with best-in-class innovation, reliable supply and quality compliance.’
